<SEC-DOCUMENT>0001213900-25-041712.txt : 20250512
<SEC-HEADER>0001213900-25-041712.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512070007
ACCESSION NUMBER:		0001213900-25-041712
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250512
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		25932529

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0241707-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>May
2025</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp; <B>001-38723</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 12, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued this 6K announcing, that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55
per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital., a copy of which is furnished
as Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Announcement is furnished herewith as Exhibit 99.1 to this Report
on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for the
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: May 12, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="ea024170701ex99-1_tiziana.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tiziana Life Sciences LTD Press Release, dated May 12, 2025</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024170701ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 12, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences Announces Purchase of
Shares by Chairman</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>New York, May 12, 2025</B>&nbsp;&ndash; Tiziana Life Sciences Ltd.
(Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation
therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that
its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding
to 43,252,143 common shares, which is 37.02% of issued share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological
drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November
of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human
diseases.<SUP>[1],[2]</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical
development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology
for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline
applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana Life Sciences and its innovative
pipeline of therapies, please visit www.tizianalifesciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[1]</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[2]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 28# 2(  A$! Q$!_\0
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M@K [2T>#CM]RKOQ]N[G3OAS;BSN);?=?11L8W*DKL<X)';('Y5ZM7D?[1/\
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M KW*#]GWP5'$%D_M&9N[M<8)_ "@#C_&NO\ PE\<ZM#J6HZSJL,\<0A_<6[
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M']#70P_M(ZW'$J3^'[)Y0,,PE=03].<5]'D C!Y%56TVQ=BSV5LS'J3$I/\
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M+RZM;V\=Q(DT4820D#YW"D\?6NC!R :X#XS_ /).;C_KZMO_ $:M=^OW1]*
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M6P8Z_;64%X'( LY&="O8_,,@]>*P/&/BG6=(U_0]&T2QLKFYU/S<&[D9%78
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B\(]/MM;AO=;U9&O]2.(/M%U(TI$?7: Q( R!THHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
